Relay Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue: | |||
| License and other revenue | $15,355 | $10,007 | $25,546 |
| Total revenue | 15,355 | 10,007 | 25,546 |
| Operating expenses: | |||
| Research and development expenses | $261,383 | $319,089 | $330,018 |
| Change in fair value of contingent consideration liability | — | (13,206) | (6,422) |
| General and administrative expenses | 56,710 | 76,592 | 74,950 |
| Total operating expenses | 318,093 | 382,475 | 398,546 |
| Loss from operations | (302,738) | (372,468) | (373,000) |
| Other income: | |||
| Interest income | 27,035 | 34,746 | 31,045 |
| Other (expense) income | (776) | 14 | (18) |
| Total other income, net | 26,259 | 34,760 | 31,027 |
| Net loss | $(276,479) | $(337,708) | $(341,973) |
| Net loss per share, basic and diluted | $(1.61) | $(2.36) | $(2.79) |
| Weighted average shares of common stock, basic and diluted | 171,586,558 | 142,867,844 | 122,576,527 |
| Other comprehensive income (loss): | |||
| Unrealized holding gain (loss) | 1,724 | (795) | 10,224 |
| Total other comprehensive income (loss) | 1,724 | (795) | 10,224 |
| Total comprehensive loss | $(274,755) | $(338,503) | $(331,749) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.